These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22742455)

  • 1. Warfarin therapy in the HIV medical home model: low rates of therapeutic anticoagulation despite adherence and differences in dosing based on specific antiretrovirals.
    Anderson AM; Chane T; Patel M; Chen S; Xue W; Easley KA
    AIDS Patient Care STDS; 2012 Aug; 26(8):454-62. PubMed ID: 22742455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective assessment of a nomogram for the initiation of oral anticoagulation therapy for outpatient treatment of venous thromboembolism.
    Kovacs MJ; Anderson DA; Wells PS
    Pathophysiol Haemost Thromb; 2002; 32(3):131-3. PubMed ID: 12372927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.
    Röshammar D; Simonsson US; Ekvall H; Flamholc L; Ormaasen V; Vesterbacka J; Wallmark E; Ashton M; Gisslén M
    J Pharmacokinet Pharmacodyn; 2011 Dec; 38(6):727-42. PubMed ID: 21964996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A probable interaction between warfarin and the antiretroviral TRIO study regimen.
    Liedtke MD; Vanguri A; Rathbun RC
    Ann Pharmacother; 2012 Nov; 46(11):e34. PubMed ID: 23115227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
    Di Biagio A; Prinapori R; Giannarelli D; Maggiolo F; Di Giambenedetto S; Borghi V; Penco G; Cicconi P; Francisci D; Sterrantino G; Zoncada A; Monno L; Capetti A; Giacometti A;
    J Antimicrob Chemother; 2013 Jan; 68(1):200-5. PubMed ID: 22915463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study.
    Chitsike RS; Rodger MA; Kovacs MJ; Betancourt MT; Wells PS; Anderson DR; Chagnon I; LE Gal G; Solymoss S; Crowther MA; Perrier A; White RH; Vickars LM; Ramsay T; Kahn SR
    J Thromb Haemost; 2012 Oct; 10(10):2039-44. PubMed ID: 22846068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a pharmacist-managed inpatient anticoagulation service for warfarin initiation and titration.
    Wong YM; Quek YN; Tay JC; Chadachan V; Lee HK
    J Clin Pharm Ther; 2011 Oct; 36(5):585-91. PubMed ID: 21070296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study.
    Clark NP; Witt DM; Delate T; Trapp M; Garcia D; Ageno W; Hylek EM; Crowther MA;
    Pharmacotherapy; 2008 Aug; 28(8):960-7. PubMed ID: 18657012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous Thromboembolism Requiring Extended Anticoagulation Among HIV-Infected Patients in a Rural, Resource-Constrained Setting in Western Kenya.
    Kanyi J; Karwa R; Pastakia SD; Manji I; Manyara S; Saina C
    Ann Pharmacother; 2017 May; 51(5):380-387. PubMed ID: 28056524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery.
    Meijer K; Kim YK; Carter D; Schulman S
    Thromb Haemost; 2011 Feb; 105(2):232-8. PubMed ID: 21173999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential interaction involving warfarin and ritonavir.
    Knoell KR; Young TM; Cousins ES
    Ann Pharmacother; 1998 Dec; 32(12):1299-302. PubMed ID: 9876810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial.
    Kovacs MJ; Rodger M; Anderson DR; Morrow B; Kells G; Kovacs J; Boyle E; Wells PS
    Ann Intern Med; 2003 May; 138(9):714-9. PubMed ID: 12729425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence?
    Cohen AT; Maillardet L; Yavin Y
    Thromb Haemost; 2009 Mar; 101(3):422-7. PubMed ID: 19277401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology of subtherapeutic anticoagulation in the United States.
    Rose AJ; Ozonoff A; Grant RW; Henault LE; Hylek EM
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):591-7. PubMed ID: 20031897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of warfarin therapy managed by pharmacists via hospital anticoagulation clinic versus online anticoagulation clinic.
    Cao H; Wu J; Zhang J
    Int J Clin Pharm; 2018 Oct; 40(5):1072-1077. PubMed ID: 29956134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
    Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK
    Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A potential interaction between warfarin and atovaquone.
    Hidalgo K; Lyles A; Dean SR
    Ann Pharmacother; 2011 Jan; 45(1):e3. PubMed ID: 21189363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Search for predictors of nontherapeutic INR results with warfarin therapy.
    McGriff-Lee NJ; Csako G; Chen JT; Dang DK; Rosenfeld KG; Cannon RO; Macklin LR; Wesley RA;
    Ann Pharmacother; 2005 Dec; 39(12):1996-2002. PubMed ID: 16288081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A feasibility study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboembolic risk.
    Larson BJ; Zumberg MS; Kitchens CS
    Chest; 2005 Mar; 127(3):922-7. PubMed ID: 15764777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalent aetiologies of non-therapeutic warfarin anticoagulation in a network of pharmacist-managed anticoagulation clinics.
    Cryder B; Felczak M; Janociak J; Dela Pena L; Allen S; Gutierrez P
    J Clin Pharm Ther; 2011 Feb; 36(1):64-70. PubMed ID: 21198721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.